Corporate Governance
Catalent CEO drops FY2023 revenue forecast by $450m after “disappointing” quarter
In an investor call on 19 May, Catalent reduced its annual net revenue forecast by approximately 10% compared to its February predictions.
Inflation drives pharma manufacturing to focus on sustainability
ESG innovation among pharma companies has dropped off in the last year
North America is seeing a hiring boom in pharmaceutical industry ESG roles
Macro view: Omicron outbreak forces lockdown in New South Wales
ESG in clinicals trials: What pharma needs to know
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox